MONTREAL, June 5 /PRNewswire-FirstCall/ -- ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") announced today that the official signing ceremony for the strategic alliance concluded earlier this year with the Wuhan Institute of Biological Products ("WIBP") a subsidiary of China National Biotec Group ("CNBG") was held on Wednesday, June 4, 2008 at CNBG's Beijing location.
Present at the signing were CNBG's President and Chief Executive Officer Ms. Lifeng Wang, WIBP's Director Dr. Xiaoming Yang, ProMetic's President and Chief Executive Officer Mr. Pierre Laurin as well as several officials from the CNBG and WIBP organizations. Additional information is available on CNBG's web site at www.cnbgint.com and on WIBP's web site at www.wibp.com.cn/en.
More about Wuhan Institute of Biological Products
WIBP (www.wibp.com.cn or www.wibp.com.cn/en), located in Wuhan, China. is one of the subsidiaries of CNBG, has over 50 years experience in the fields of biomedical research and product development; historically strong in R&D, WIBP is the only institute certified by state to offer doctoral program among six Institute of Biological Products in CNBG. Today, WIBP has more than 1,000 employees, and major products include two dozen vaccines and plasma derivatives currently marketed throughout the China.
More about China National Biotec Group
CNBG (www.cnbgint.com or www.cnbg.com.cn), headquartered in Beijing, China, is a state-owned enterprise and the largest biotech company in China dedicated to discover, develop, manufacture and market a broad range of human health products, including vaccines, blood derivatives, biopharmaceuticals, diagnostic reagents and others. With more than 9,000 employees and revenues of 421 million USD in 2006, CNBG is the largest producer of vaccines and blood derivatives in China, enjoying more than 80% and 30% market share respectively. The company consists of 6 Institute of Biological Products and an international trading company.
About ProMetic Life Sciences Inc.
ProMetic (www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montreal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the U.S., Europe, Asia and in the Middle-East.
SOURCE ProMetic Life Sciences Inc.